Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - Protalix BioTherapeutics, Inc. | v432711_ex31-2.htm |
| EX-32.2 - EXHIBIT 32.2 - Protalix BioTherapeutics, Inc. | v432711_ex32-2.htm |
| EX-3.10 - EXHIBIT 3.10 - Protalix BioTherapeutics, Inc. | v432711_ex3-10.htm |
| EX-3.9 - EXHIBIT 3.9 - Protalix BioTherapeutics, Inc. | v432711_ex3-9.htm |
| EX-32.1 - EXHIBIT 32.1 - Protalix BioTherapeutics, Inc. | v432711_ex32-1.htm |
| EX-3.8 - EXHBIT 3.8 - Protalix BioTherapeutics, Inc. | v432711_ex3-8.htm |
| 10-K - FORM 10-K - Protalix BioTherapeutics, Inc. | v432711_10k.htm |
| EX-31.1 - EXHIBIT 31.1 - Protalix BioTherapeutics, Inc. | v432711_ex31-1.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-208004) and Registration Statements on Form S-8 (No. 333-148983, No. 333-182677 and 333-203960) of Protalix BioTherapeutics, Inc. of our report dated March 8, 2016 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ Kesselman & Kesselman
Kesselman & Kesselman
Certified Public Accountants (lsr.)
A member firm of PricewaterhouseCoopers International Limited
Tel-Aviv, Israel
March 8, 2016